Sectors
PVLA
Palvella Therapeutics, Inc.
152.59
2 x 111.17
2 x 195.41
bid
ask
+
2.62
1.75%
2 @ 05:46 PM
154.10 +1.51 (0.99%)
| Ytd | 45.78% | |
| 1y | 181.79% |
143.47
day range
152.89
50.82
52 week range
161.38
| Open | 147.95 | Prev Close | 149.97 | Low | 143.47 | High | 152.89 | Mkt Cap | 2.20B |
| Vol | 245.68K | Avg Vol | 256.42K | EPS | -4.86 | P/E | N/A | Forward P/E | -20.35 |
| Beta | -0.17 | Short Ratio | 10.65 | Inst. Own | 104.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 145.34 | 200-d Avg | 117.06 | 1yr Est | 230.53 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-10 | 2026-09 | -1.77 | N/A | N/A | N/A |
| 2026-08-04 | 2026-06 | -1.17 | -1.52 | -0.35 | -29.91% |
| 2026-05-07 | 2026-03 | -0.9 | -1.2 | -0.3 | -33.33% |
| 2026-03-31 | 2025-12 | -0.91 | -1.08 | -0.17 | -18.53% |
| 2025-11-11 | 2025-09 | -0.85 | -1.03 | -0.18 | -21.18% |
| 2025-08-14 | 2025-06 | -0.78 | -0.86 | -0.08 | -10.26% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-05-21 | Stephens & Co. | Upgrade | Overweight | Overweight |
| 2026-05-21 | Chardan Capital | Upgrade | Buy | Buy |
| 2026-05-12 | Stephens & Co. | Upgrade | Overweight | |
| 2026-03-31 | Chardan Capital | Upgrade | Buy | Buy |
| 2026-03-24 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-03-16 | Chardan Capital | Upgrade | Buy | Buy |
Profile
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-08-18 | GOIN KATHLEEN | Chief Operating Officer | 0.00 | Sale |
| 2026-02-26 | HERON ELAINE J | Director | 53.69K | Purchase |
| 2026-03-29 | JENKINS GEORGE M | Director | 201.13K | Purchase |
| 2026-06-11 | KORENBERG MATTHEW E | Chief Financial Officer | 1000 | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Montanova Capital LLC | 1.14M | 173.25M | 7.88% |
| 2026-06-29 | Jennison Associates LLC | 960.62K | 146.58M | 6.67% |
| 2026-06-29 | Blackrock Inc. | 918.36K | 140.13M | 6.37% |
| 2026-06-29 | Frazier Life Sciences Management, L.P. | 882.40K | 134.65M | 6.12% |
| 2026-06-29 | First Light Asset Management, LLC | 771.90K | 117.78M | 5.36% |
| 2026-06-29 | BVF Inc. | 672.79K | 102.66M | 4.67% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 407.17K | 62.13M | 2.83% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 361.69K | 55.19M | 2.51% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 ETF | 281.59K | 42.97M | 1.95% |
| 2026-04-29 | Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund | 276.56K | 42.20M | 1.92% |
| 2026-03-30 | MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 231.48K | 35.32M | 1.61% |
| 2026-06-29 | PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 208.83K | 31.86M | 1.45% |